Finance

ADMA Biologics Faces Investor Lawsuit Over Fraud

By Daybreak Brief Editorial Team

ADMA Biologics is in hot water as a class action lawsuit kicks off, accusing the company of cooking the books and misleading investors. The Schall Law Firm is leading the charge, and they want any investors who bought ADMA shares between August 2024 and March 2026 to get in on the action before the August 10, 2026 deadline. What does it mean for you? If you lost money by investing in ADMA during the specified period, you might have a shot at recovering some of your losses by joining this lawsuit. Better call your lawyer, or maybe just click that link!

Original source Read the full story →
▲ 1,347 voters this week
How we select stories →
More from this briefing
Compex Legal's $872K Data Breach Payout Deadline → Venus: Earth's Cautionary Tale of Greenhouse Effects → Roblox Faces Investor Lawsuit Over Misleading Claims → AeroVironment Faces Lawsuit Over Investor Misleading → Hermès Under Fire for Alleged Price Hikes → ZoomInfo Faces Lawsuit Over Misleading Growth Claims → ONE Carmel Offers Luxurious Coastal Living → ONE Carmel Unveils Luxury Homes in Coastal Paradise → Mergers Alert: Equity and NextEra Shake-Up → Monteverde Probes Twin Vee Merger Fairness → Brazil Probes Google's AI-Driven News Practices → UK Heatwave Crisis: Urgent Call for Cooling Solutions → AI Tutors Rise, But Can't Replace Humans Yet → Flash Floods Fueling Nationwide Disaster Fatigue → Hennes Communications Tops Crisis PR Rankings Again →

Get stories like this every morning.

Five-minute intelligence briefing — in your inbox at 6 AM.

Subscribe now →